today announced that Biocartis,
an innovative molecular diagnostics company, has selected ThingWorx as
the Machine-to-Machine (M2M) application platform to power its
next-generation remote service offering. Biocartis intends to use the
ThingWorx application platform to provide remote instrument connectivity
and innovative M2M applications, extending its molecular diagnostics
solution with high-value remote service and value-added offerings for
its customers and partners.
ThingWorx enables Biocartis to bring to market a next-generation remote
service solution for its Molecular Diagnostics Platform, a unique
DNA-based in vitro diagnostics system that it is currently developing
for the emerging needs of personalized medicine. Biocartis is utilizing
the rapid application development tools and M2M communications
technology provided by the ThingWorx platform to develop the remote
service solution. Using the extensibility and enterprise integration
features that are core to the ThingWorx platform, Biocartis aims to
deliver innovative, value-added services in addition to remote
"We are entering the 'connected age', an age that brings people,
systems, and the '50 billion things'-sensors, devices, machines-together
to provide the opportunity for a step change in operational innovation
and resource efficiency," said Rudi Pauwels, CEO of Biocartis.
"ThingWorx uniquely enables rganizations to rapidly build and run
connected applications to capture the business opportunities offered by
the emerging pervasiveness of smart things."
"We are pleased to be selected by Biocartis, an innovator in the
molecular diagnostics industry," said Russ Fadel, CEO of ThingWorx. "The
rapid time to market provided by ThingWorx, combined with the platform's
unique connectivity and business integration capabilities, enables our
customers to create a competitive advantage in their markets. Biocartis'
selection of ThingWorx further validates our position as the leader in
next-generation connected application development."
Biocartis aims to improve healthcare outcomes by enabling the practice
of personalized medicine anywhere, anytime. Biocartis' ambition is to
establish a new gold standard in diagnostic testing.
Biocartis' innovative research and diagnostic systems are characterized
by multiplex detection and simplified workflows, which require less
hands-on time and minimize sample requirements (especially for tumor
biopsies). Additionally, Biocartis develops assays that have high
clinical utility and compelling health economic value. Oncology is the
primary focus of Biocartis as this is one of the greatest unmet needs
for personalized medicine. Biocartis is well suited to address the
growing need for individualized diagnosis and treatment of cancer
Biocartis is a rapidly growing company; to date Biocartis staff includes
over 150 people. In December 2012, Biocartis launched its High Multiplex
Detection Platform, and has thus evolved from a late-stage development
company into a commercial business. For more information, visit www.biocartis.com.
ThingWorx™ provides the first platform designed to efficiently build and
run the applications of today's connected world. ThingWorx's model-based
design and search-based intelligence reduces application development
efforts by 10X, minimizing cost, risk and time to market. The ThingWorx
platform combines the key functionality of Web 2.0, search, and social
collaboration, and applies it to the world of "things", including
connected products, machines, sensors, and industrial equipment.
Businesses use the ThingWorx platform to rapidly deliver innovative
applications and connected solutions across markets ranging from
manufacturing, energy, and food, to Machine-to-Machine (M2M) remote
monitoring and service, as well as in emerging Internet of Things
applications, including smart cities, smart grid, agriculture, and
transportation. For more information, please visit our website at www.thingworx.com
and our blog at www.thingworx.com/blog
or follow us on Twitter at @ThingWorx.
[ Back To NFVZone's Homepage ]